Prostate cancer. Malignant neoplasm of prostate
Conditions
Interventions
Intervention 1: Intervention group: Metformin tablet at a dose of 1000 mg orally once a day will be prescribed before starting radiation therapy by one month after the final session of radiotherapy. I
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Patients with localized prostate cancers that undergo definitive or postoperative external radiotherapy
Exclusion criteria
Exclusion criteria: Patients with metastatic prostate cancer Patients previously treated with radiotherapy or chemotherapy Patients with renal or liver dysfunction Patients with severe respiratory diseases (such as obstructive pulmonary disorders or severe asthma) Patients with hematological disorders (such as severe anemia or vitamin B12 deficiency) Diabetic patients Smoker patients Metformin hypersensitivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiation protection effect. Timepoint: At 0, every two weeks during radiotherapy course and one month after the final session of radiotherapy. Method of measurement: Oxidative stress tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| Urogenital complications. Timepoint: At 0, every two weeks during radiotherapy course and one month after the final session of radiotherapy. Method of measurement: Toxicity Criteria of the Radiation Therapy Oncology Group. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSasan Razmjoo
Ahvaz University of Medical Sciences
Outcome results
None listed